Incyte Corp (INCY)
$7.54
-0.01 (-0.13%)
| CAPS Rating |
|
|---|---|
| Open | $7.66 |
| Previous Close | $7.55 |
| Daily Range | $6.82 - $7.83 |
| 52-Week Range | $1.85 - $8.32 |
| Market Cap | $893.79M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,726,911 |
| Average Daily Volume | 2,899,000 |
How do you think INCY will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
INCY Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
INCY News and Commentary
- UPDATE 1-Incyte to sell 18 mln shares, $250 mln in senior notes – Reuters
- UPDATE 1-Incyte says psoriasis drug meets main goal – Reuters
- Wall Street's Buy List – The Motley Fool
- Leave a date on your limit order starts in a pitch for reference – Blog at The Motley Fool
- 10 Stocks Shaking the Market – The Motley Fool
- Today's 5-Star Movers – The Motley Fool
- 5-Star Stocks on the Upswing – The Motley Fool
- A One-Hit Wonder Goes for No. 2 – The Motley Fool
- Some Insight Into Incyte's Data – The Motley Fool
- BIOTECHS ROCK – Blog at The Motley Fool
- Closing Incyte (INCY) underperform – Blog at The Motley Fool
- Tuesday's Top 5 Growth Winners – The Motley Fool
- Monday's Top 4 Growth Winners – The Motley Fool
- Stopping the Inflammation – The Motley Fool
- Turnaround Time for Biotech? – The Motley Fool
- Incyte's Double Dose of Trial News – The Motley Fool
- This Just In: Upgrades & Downgrades – The Motley Fool
Related News and Articles
- A Big Upgrade for Allos Therapeutics – The Motley Fool


RSS Headlines
Fool UK